| Effect | Increase |
| Trial Design | Randomized trial |
| Trial Length | 1-6 months |
| Number of Subjects | 96 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
EGb-761 appears to be equally effective as Donezepil in reducing cognitive impairment associated with Alzheimer's, although combination therapy was more effective than either in isolation.
